BioBridge Brain-Spinal Interface Enables Paraplegic Patients to Walk Again: Milestone Breakthrough in Spinal Cord Injury Treatment

BioBridge Brain-Spinal Interface Enables Paraplegic Patients to Walk Again: Milestone Breakthrough in Spinal Cord Injury Treatment

Switzerland's EPFL (École Polytechnique Fédérale de Lausanne) today published a paper in Nature reporting that its BioBridge brain-spinal cord interface system has successfully restored independent walking in three patients with complete spinal cord injuries (ASIA Grade A). This is the first time brain-computer interface technology has achieved walking restoration in complete paraplegia.

The BioBridge system comprises two implantable modules: a 128-channel cortical electrode array implanted in the motor cortex to decode movement intentions, and a spinal epidural stimulator implanted below the injury site to convert decoded motor commands into precise electrical stimulation sequences that activate lower limb motor neurons.

EPFL neuroengineering professor Grégoire Courtine, the project's lead researcher, described the system's mechanism in the paper: "BioBridge creates a digital bridge between the brain and spinal cord. When a patient imagines taking a step, neural signals from the motor cortex are captured by the cortical electrodes, converted in real time by an AI decoder into spinal stimulation parameters, and precisely activate the corresponding muscle groups."

All three participants had complete thoracic spinal cord transections from traffic accidents, with injury durations ranging from 3 to 7 years. After 6 months of rehabilitation training, all three regained independent walking with walker assistance, and two could walk short distances unassisted. Gait analysis showed naturalness at 72% of normal, with walking speed at 45% of normal.

From Laboratory to Clinical Practice

Co-author Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital, performed all implantation surgeries. "The surgery itself isn't complex—we use minimally invasive techniques, and the entire implantation takes about 4 hours," she said. "The real challenge is post-operative AI model personalization training. Each patient's cortical motor representation differs, and the decoder needs to learn movement intentions from each patient's own brain signals."

BioBridge's AI decoder is based on a technique called "neural transfer learning"—first training a base model from brain-spinal signal pairs of numerous healthy subjects, then fine-tuning with small amounts of patient data. This has reduced each patient's training period from the initial 6 months to 2 weeks.

Competitive Landscape

BioBridge is not the only brain-computer interface project targeting spinal cord injury. The BrainGate consortium has previously achieved mechanical arm control in multiple tetraplegia patients, and Onward Medical's spinal stimulation technology has shown progress in incomplete spinal cord injuries.

But BioBridge's uniqueness lies in achieving "natural walking"—patients don't need continuous external device support. Once activated, the implanted system makes walking feel as natural as it does for able-bodied individuals. Onward Medical CEO Dave Marver commented: "BioBridge's results are remarkable. We're evaluating a potential collaboration with EPFL to combine our spinal stimulation technology with BioBridge's brain decoding capabilities."

Ethics and Accessibility

However, BioBridge also faces ethical and accessibility questions. The total system cost is estimated at $350,000–$500,000, well beyond most patients' means. WHO spinal cord injury program lead Alana Officer stated: "Globally, about 500,000 new spinal cord injuries occur annually, 90% in low- and middle-income countries. If this technology serves only a handful of wealthy patients, it will worsen global health inequalities."

Additionally, the long-term safety of brain implants remains to be verified. The longest follow-up among the three participants is 18 months, with no serious adverse events yet, but electrode biocompatibility in brain tissue, infection risk, and signal degradation require evaluation in larger clinical trials.

The EPFL team plans to initiate a 50-patient multicenter Phase II clinical trial in 2029, with approval from Swiss and French regulators already secured. Professor Courtine stated: "Our goal isn't to help a few people stand up—it's to build a scalable spinal cord injury treatment protocol. BioBridge is just the beginning."